Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Other Accumulated Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Other Accumulated Expenses for 4 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 1132.14% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a 1132.14% increase, with the full-year FY2024 number at $75000.0, up 167.86% from a year prior.
  • Other Accumulated Expenses was $1.0 million for Q3 2025 at Century Therapeutics, up from $49000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q3 2025 to a low of $11000.0 in Q2 2023.
  • A 4-year average of $164000.0 and a median of $75000.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 88.14% in 2023, then soared 1132.14% in 2025.
  • Century Therapeutics' Other Accumulated Expenses stood at $236000.0 in 2022, then crashed by 88.14% to $28000.0 in 2023, then surged by 167.86% to $75000.0 in 2024, then surged by 1280.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Other Accumulated Expenses are $1.0 million (Q3 2025), $49000.0 (Q2 2025), and $111000.0 (Q1 2025).